On January 2, 2019, the Arterial Network learned from foreign media information that Fresenius said it is still seeking US Federal Trade Commission (FTC) approval of its $2 billion with NxStage Medical (NASDAQ: NXTM) Merger application.
NxStage Medical delayed the merger in October 2017 due to a survey by the Federal Trade Commission. The program was originally announced in August 2017 and has been in progress for almost a year and a half.
According to foreign media reports, Fresenius Medical Care said in the latest news released late last week that it is still seeking approval from the US Federal Trade Commission, and the acquisition is expected to be completed early next year.
Although Fresenius Medical Care wants to complete NxStage Medical by the end of 2018? The acquisition, but the expected acquisition deadline was postponed from October 2019 to February 5, 2019.
In July of this year, the German kidney care giant and the American medical technology company NxStage Medical? The deadline for the transaction was extended from August 7 to November 5 for a total of 90 days, but they said they still hope to complete the transaction within 2018.
The Federal Trade Commission said a year ago that it wants more information about the details of the deal; Fresenius Medical Care is NxStage Medical? Customers, this will complicate the impact of this acquisition on antitrust. In July 2017, NxStage agreed to trade its Medisystems lineage business to B. Braun, to quell the concerns of the US Federal Trade Commission.
Fresenius Medical Care's acquisition of NxStage Medical aims to further strengthen and strengthen the company's leadership in global family dialysis and expand the US market for critical care.
Household Gloves,Gloves Microfiber,Flock Lined Glove,Household Latex Work Glove
ZHANGJIAGANG DINSHENGLIN TRADING CO.,LTD , https://www.dslhouse.com